Logo image of RPID

RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

NASDAQ:RPID - Nasdaq - US75340L1044 - Common Stock - Currency: USD

3.21  -0.45 (-12.3%)

After market: 3.12 -0.09 (-2.8%)

Fundamental Rating

2

RPID gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. RPID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RPID is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPID has reported negative net income.
RPID had a negative operating cash flow in the past year.
In the past 5 years RPID always reported negative net income.
In the past 5 years RPID always reported negative operating cash flow.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

The Return On Assets of RPID (-45.72%) is worse than 84.21% of its industry peers.
RPID's Return On Equity of -57.36% is on the low side compared to the rest of the industry. RPID is outperformed by 68.42% of its industry peers.
Industry RankSector Rank
ROA -45.72%
ROE -57.36%
ROIC N/A
ROA(3y)-33.6%
ROA(5y)-49.88%
ROE(3y)-38.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

RPID does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RPID has more shares outstanding
RPID has a worse debt/assets ratio than last year.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

RPID has an Altman-Z score of -2.31. This is a bad value and indicates that RPID is not financially healthy and even has some risk of bankruptcy.
RPID's Altman-Z score of -2.31 is on the low side compared to the rest of the industry. RPID is outperformed by 80.70% of its industry peers.
RPID has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, RPID is doing good in the industry, outperforming 77.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.31
ROIC/WACCN/A
WACC11.33%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

RPID has a Current Ratio of 5.52. This indicates that RPID is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RPID (5.52) is better than 75.44% of its industry peers.
A Quick Ratio of 4.19 indicates that RPID has no problem at all paying its short term obligations.
RPID's Quick ratio of 4.19 is fine compared to the rest of the industry. RPID outperforms 68.42% of its industry peers.
Industry RankSector Rank
Current Ratio 5.52
Quick Ratio 4.19
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

RPID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.04%, which is quite good.
RPID shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.29%.
RPID shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.88% yearly.
EPS 1Y (TTM)17.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)27.29%
Revenue growth 3Y11.88%
Revenue growth 5YN/A
Sales Q2Q%23.74%

3.2 Future

The Earnings Per Share is expected to grow by 9.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 25.82% on average over the next years. This is a very strong growth
EPS Next Y9.43%
EPS Next 2Y10.94%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue Next Year23.02%
Revenue Next 2Y21.24%
Revenue Next 3Y25.82%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RPID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.94%
EPS Next 3Y9.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (2/21/2025, 8:00:01 PM)

After market: 3.12 -0.09 (-2.8%)

3.21

-0.45 (-12.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-01 2024-11-01/bmo
Earnings (Next)02-28 2025-02-28/amc
Inst Owners54.35%
Inst Owner Change-3.81%
Ins Owners2.51%
Ins Owner Change-0.31%
Market Cap138.13M
Analysts85
Price Target8.16 (154.21%)
Short Float %0.39%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.36%
Min EPS beat(2)-2.76%
Max EPS beat(2)0.04%
EPS beat(4)2
Avg EPS beat(4)1.88%
Min EPS beat(4)-4.8%
Max EPS beat(4)15.03%
EPS beat(8)5
Avg EPS beat(8)2.98%
EPS beat(12)6
Avg EPS beat(12)0.13%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)10.98%
Min Revenue beat(2)8.14%
Max Revenue beat(2)13.82%
Revenue beat(4)4
Avg Revenue beat(4)5.75%
Min Revenue beat(4)0.02%
Max Revenue beat(4)13.82%
Revenue beat(8)7
Avg Revenue beat(8)8.04%
Revenue beat(12)8
Avg Revenue beat(12)2.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.22%
EPS NQ rev (3m)-2.22%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.77%
Revenue NQ rev (1m)2.63%
Revenue NQ rev (3m)2.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.28
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.61
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.72%
ROE -57.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.6%
ROA(5y)-49.88%
ROE(3y)-38.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.16%
Cap/Sales 6.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.52
Quick Ratio 4.19
Altman-Z -2.31
F-Score4
WACC11.33%
ROIC/WACCN/A
Cap/Depr(3y)169.07%
Cap/Depr(5y)133.87%
Cap/Sales(3y)20.47%
Cap/Sales(5y)15.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y9.43%
EPS Next 2Y10.94%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue 1Y (TTM)27.29%
Revenue growth 3Y11.88%
Revenue growth 5YN/A
Sales Q2Q%23.74%
Revenue Next Year23.02%
Revenue Next 2Y21.24%
Revenue Next 3Y25.82%
Revenue Next 5YN/A
EBIT growth 1Y15.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.17%
EBIT Next 3Y11.02%
EBIT Next 5YN/A
FCF growth 1Y32.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.81%
OCF growth 3YN/A
OCF growth 5YN/A